306960-30-5

Upstream product

• 3473-63-0 formamidine acetic acid 
• 306960-29-2 2-amino-3-cyano-1H-pyrid-4-one 
• 5417-82-3 (1-ethoxyethylidene)malononitrile 
• 7440-44-0 pyrographite 
• 98651-70-8 2-amino-4-methoxypyridine-3-carbonitrile 
• 92277-14-0 O-acetylformamidoxime 

Downstream Products

• 1053253-53-4 benzoic acid 4-acetoxy-5-(4-amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-tetrahydro-furan-2-ylmethyl ester 
• 376393-89-4 C₂₈H₂₄N₄O₈ 
• 306960-35-0 C₂₈H₂₄N₄O₈ 
• 1026980-17-5 benzoic acid 4-acetoxy-5-(4-amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)-3-methylene-tetrahydro-furan-2-ylmethyl ester 
• 1054653-88-1 C₂₉H₂₆N₄O₈ 
• 385435-82-5 C₃₄H₂₈N₄O₈ 
• 1054613-29-4 C₃₅H₃₀N₄O₈ 
• 1053255-08-5 C₃₅H₂₈N₄O₈ 
• 385435-85-8 C₄₁H₃₂N₄O₁₀ 

Relevant academic research and scientific papers

Pyridopyrimidinones

The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and X′ have the designations cited in patent claim 1. Said c

Sulfonamides

Compounds of the formula (I), in which R6, R7, R8, R9 and X have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for t

SULFONAMIDES

The invention relates to compounds of formula (I) in which R6, R7, R8, R9 and X have the meanings cited in Claim 1. These compounds are inhibitors of tyrosinkinases, particularly TIE-2, and Raf kinases and can, among other things, be used for treating tumors.

PYRIDOPYRIMIDINONES

The invention relates to compounds of formula (I) wherein R1, R2 , R3 , R4 , R5, R6 , R7 , R8, R9, X and X' have the designations cited in patent claim 1. Said compounds are inhibitors of tyrosine kinases, especially TIE-2, and Raf kinases, and can, inter alia, be used for the treatment of tumours.

Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides

A purine nucleoside analog includes a pyrido[2,3-d]pyrimidine or a pyrimido[4,5-d]pyrimidine and further has a sugar moiety that is optionally modified at the C2′, C3′, C4′ and/or C5′ position. Particularly contemplated compounds also include prodrug forms of the purine nucleoside analogs, and both purine nucleoside analogs and the corresponding prodrugs are employed in the reduction of growth of neoplastic cells.

Synthesis and cytotoxicity of 4-amino-5-oxopyrido[2,3-d]pyrimidine nucleosides

A number of nucleoside analogues have been either used clinically as anticancer drugs or evaluated in clinical studies, while new nucleoside analogues continue to show promise. In this article, we report synthesis and cytotoxicity of a series of new pyrid